Literature DB >> 23357860

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

Olivier Adotévi1, Magalie Dosset, Jeanne Galaine, Laurent Beziaud, Yann Godet, Christophe Borg.   

Abstract

Current cancer immunotherapies predominantly rely on CD8(+) T cells to fight against tumors. However accumulative evidence showed that proinflammatory CD4(+) helper T cells are critical determinants of effective antitumor immunity. The utilization of universal tumor-reactive helper peptides from telomerase represents a powerful approach to the fully use of CD4(+) T cell-based immunotherapy.

Entities:  

Keywords:  CD4 T cell; cancer vaccine; helper peptide; telomerase

Mesh：

Substances：

Year:  2013        PMID： 23357860      PMCID： PMC3899142          DOI： 10.4161/hv.23587

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  42 in total

Review 1.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

2.  In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help.

Authors:  C Fayolle; E Deriaud; C Leclerc
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

3.  Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells.

Authors:  S B Justin Wong; Rinke Bos; Linda A Sherman
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

4.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.

Authors:  Todd A Fehniger; Megan A Cooper; Gerard J Nuovo; Marina Cella; Fabio Facchetti; Marco Colonna; Michael A Caligiuri
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

Review 5.  Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins.

Authors:  Paula Martínez; María A Blasco
Journal:  Nat Rev Cancer       Date:  2011-03       Impact factor: 60.716

Review 6.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

Authors:  K L Knutson; M L Disis
Journal:  Cancer Immunol Immunother       Date:  2005-01-27       Impact factor: 6.968

7.  Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.

Authors:  Olivier Adotévi; Karine Mollier; Christine Neuveut; Magalie Dosset; Patrice Ravel; Wolf-Hervé Fridman; Eric Tartour; Pierre Charneau; Simon Wain-Hobson; Pierre Langlade-Demoyen
Journal:  Blood       Date:  2010-02-03       Impact factor: 22.113

8.  High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

Authors:  David-Alexandre Gross; Stéphanie Graff-Dubois; Paule Opolon; Sébastien Cornet; Pedro Alves; Annelise Bennaceur-Griscelli; Olivier Faure; Philippe Guillaume; Hüseyin Firat; Salem Chouaib; François A Lemonnier; Jean Davoust; Isabelle Miconnet; Robert H Vonderheide; Kostas Kosmatopoulos
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 9.  Telomerase and cancer therapeutics.

Authors:  Calvin B Harley
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

10.  CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help.

Authors:  Yusuke Nakanishi; Bao Lu; Craig Gerard; Akiko Iwasaki
Journal:  Nature       Date:  2009-11-08       Impact factor: 49.962
View more
  5 in total

1.  Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Authors:  Caroline Laheurte; Jeanne Galaine; Laurent Beziaud; Magalie Dosset; Jerome Kerzerho; Claire Jacquemard; Béatrice Gaugler; Christophe Ferrand; Anne Dormoy; François Aubin; Pascale Jacoulet; Virginie Westeel; Christophe Borg; Eric Tartour; Yann Godet; Bernard Maillère; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 2.  Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Authors:  Jeanne Galaine; Christophe Borg; Yann Godet; Olivier Adotévi
Journal:  Vaccines (Basel)       Date:  2015-06-30

3.  Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.

Authors:  Romain Loyon; Marine Jary; Bérengère Salomé; Alejandra Gomez-Cadena; Jeanne Galaine; Marie Kroemer; Pedro Romero; Sara Trabanelli; Olivier Adotévi; Christophe Borg; Camilla Jandus
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

Review 4.  Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms.

Authors:  Rong En Tay; Emma K Richardson; Han Chong Toh
Journal:  Cancer Gene Ther       Date:  2020-05-27       Impact factor: 5.987

Review 5.  Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy.

Authors:  Myriam Ben Khelil; Yann Godet; Syrine Abdeljaoued; Christophe Borg; Olivier Adotévi; Romain Loyon
Journal:  Cancers (Basel)       Date:  2022-01-05       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.